W. Gregory

发表

Burnout and psychiatric disorder among cancer clinicians.

J. Graham, A. Ramirez, D. Snashall, 1995, British Journal of Cancer.

ZOLEDRONIC ACID (ZOL) SIGNIFICANTLY REDUCES SKELETAL-RELATED EVENTS (SRES) VERSUS CLODRONATE (CLO) IN PATIENTS (PTS) WITH MULTIPLE MYELOMA (MM): RESULTS OF THE MEDICAL RESEARCH COUNCIL (MRC) MYELOMA IX STUDY

G. Morgan, G. Jackson, S. Bell, 2010 .

Clinical pharmacokinetics of epirubicin: the importance of liver biochemistry tests.

N. Dobbs, C. Twelves, R. Rubens, 1992, British Journal of Cancer.

Psychiatric disorder in patients with advanced breast cancer: prevalence and associated factors.

R. Rubens, A. Ramirez, W. Gregory, 1993, European journal of cancer.

In-vivo measurement of spin lattice relaxation time (T1) of bone marrow in healthy volunteers: the effects of age and sex.

R. Reznek, W. Gregory, M. Richards, 1988, The British journal of radiology.

Androgen Receptor Expression in Androgen-independent Prostate Cancer Is Associated with Increased Expression of Androgen-regulated Genes1

Katherine, Desok Kim, F. S. French, 2006 .

Androgen-regulated Genes Prostate Cancer Is Associated with Increased Expression of Androgen Receptor Expression in Androgen-independent Updated Version

Katherine, Thomas, Desok Kim, 2006 .

Edinburgh Research Explorer Mathematical modelling of tumour response in primary breast cancer

W. Gregory, 2018 .

Detection of a systemic effect of malignancy in vivo by magnetic resonance imaging.

W. Gregory, M. Richards, J. Webb, 1988, Magnetic resonance imaging.

In-vivo measurement of spin lattice relaxation time (T1) of liver in healthy volunteers: the effects of age, sex and oral contraceptive usage.

R. Reznek, W. Gregory, M. Richards, 1988, The British journal of radiology.

Mental health of hospital consultants: the effects of stress and satisfaction at work

A Cull, J. Graham, A. Ramirez, 1996, The Lancet.

Epirubicin in patients with liver dysfunction: development and evaluation of a novel dose modification scheme.

N. Dobbs, C. Twelves, R. Rubens, 2003, European journal of cancer.

Monoclonal antibody assay of serum placental alkaline phosphatase in the monitoring of testicular tumours.

W. Bodmer, P. Travers, W. Gregory, 1985, British Journal of Cancer.

Gene amplification on chromosome band 11q13 and oestrogen receptor status in breast cancer.

G. Peters, D. Barnes, V. Fantl, 1990, European journal of cancer.

The relationship between c-erbB-2 expression, S-phase fraction and prognosis in breast cancer.

J. Bártková, R. Camplejohn, W. Gregory, 1991, British Journal of Cancer.

Reproducibility of spin lattice relaxation time (T1) measurement using an 0.08 tesla MD 800 magnetic resonance imager.

R. Reznek, W. Gregory, M. Richards, 1987, The British journal of radiology.

Combination chemotherapy versus melphalan and prednisolone in the treatment of multiple myeloma: an overview of published trials.

W. Gregory, J. Malpas, M. Richards, 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Doxorubicin in advanced breast cancer: influence of schedule on response, survival and quality of life.

A. Howell, P. Hopwood, R. Swindell, 1992, European journal of cancer.

Improving the accuracy of pre-operative survival prediction in renal cell carcinoma with C-reactive protein

W. Gregory, N. Vasudev, P. Selby, 2010, British Journal of Cancer.

Does zoledronic acid (ZOL) reduce skeletal-related events (SREs) and improve progression-free survival (PFS) in patients (Pts) with multiple myeloma (MM) with or without bone disease? MRC myeloma IX study results.

G. Cook, J. Byrne, F. Ross, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Are there benefits to long-term bisphosphonate treatment in multiple myeloma (MM)? Insights from temporal analyses of zoledronic acid (ZOL) versus clodronate (CLO) in the MRC Myeloma IX Trial.

G. Cook, J. Byrne, F. Ross, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A randomised comparison of a third-generation regimen (PACEBOM) with a standard regimen (CHOP) in patients with histologically aggressive non-Hodgkin's lymphoma: a British National Lymphoma Investigation report.

K. Maclennan, W. Gregory, D. Linch, 1996, British Journal of Cancer.

Chemotherapy of advanced breast cancer: outcome and prognostic factors.

R. K. Knight, W. Gregory, C. Twelves, 1993, British Journal of Cancer.

Advanced breast cancer: use of resources and cost implications.

W. Gregory, R. Rubens, W. Gregory, 1993, British Journal of Cancer.

The relationship between c-erbB-2 expression, S-phase fraction and prognosis in breast cancer.

J. Bártková, W. Gregory, M. Richards, 1991, British Journal of Cancer.

Patient acceptability and practical implications of pharmacokinetic studies in patients with advanced cancer.

N. Dobbs, C. Twelves, A. Ramirez, 1993, European journal of cancer.

Mathematical modelling of tumour response in primary breast cancer.

W. Gregory, D. Cameron, W. Gregory, 1996, British Journal of Cancer.

Expression of sialyl-Tn predicts the effect of adjuvant chemotherapy in node-positive breast cancer.

W. Gregory, D. Miles, L. Happerfield, 1994, British Journal of Cancer.

Mathematical modelling of tumour response in primary breast cancer.

W. Gregory, A. Bowman, R. Leonard, 1996, British Journal of Cancer.